ArticleCancer research2009
Design and activity of a murine and humanized anti-CEACAM6 single-chain variable fragment in the treatment of pancreatic cancer.
Article in Cancer research, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 38 citations in OpenAlex.
- Targeted Suppression of CEACAM6 via pHLIP-Delivered RNAs in Pancreatic Ductal Adenocarcinoma.Medicina (Kaunas, Lithuania) · 2025Article
- Machine learning and gene network integration reveal prognostic subnetworks and biomarkers in pancreatic cancer.Computational and structural biotechnology journal · 2025Article
- Proteomic profiling reveals CEACAM6 function in driving gallbladder cancer aggressiveness through integrin receptor, PRKCD and AKT/ERK signaling.Cell death & disease · 2024Article
- The emerging roles of CEACAM6 in human cancer (Review).International journal of oncology · 2024Review
- Assessing the potential relevance of CEACAM6 as a blood transcriptional biomarker.F1000Research · 2022Article
- Prognostic value of the immune target CEACAM6 in cancer: a meta-analysis.Therapeutic advances in medical oncology · 2022Article
- Carcinoembryonic antigen cell adhesion molecule 6 (CEACAM6) in Pancreatic Ductal Adenocarcinoma (PDA): An integrative analysis of a novel therapeutic target.Scientific reports · 2019Article
- Integrated transcriptomic analysis reveals hub genes involved in diagnosis and prognosis of pancreatic cancer.Molecular medicine (Cambridge, Mass.) · 2019Article
- Carcinoembryonic antigen related cell adhesion molecule 6 promotes the proliferation and migration of renal cancer cells through the ERK/AKT signaling pathway.Translational andrology and urology · 2019Article
- Therapeutic Effect of pHLIP-mediated CEACAM6 Gene Silencing in Lung Adenocarcinoma.Scientific reports · 2019Article
- Article
- Oligomannose-Rich Membranes of Dying Intestinal Epithelial Cells Promote Host Colonization by Adherent-InvasiveFrontiers in microbiology · 2018Article
- Towards understanding the mechanisms of actions of carcinoembryonic antigen-related cell adhesion molecule 6 in cancer progression.Cancer science · 2018Review
- CEACAM6 as detected by the AP11 antibody is a marker notable for mucin-producing adenocarcinomas.Virchows Archiv : an international journal of pathology · 2015Article
- Emerging Role and Targeting of Carcinoembryonic Antigen-related Cell Adhesion Molecule 6 (CEACAM6) in Human Malignancies.Clinical cancer drugs · 2015Article
- Molecular targeting of CEACAM6 using antibody probes of different sizes.Journal of controlled release : official journal of the Controlled Release Society · 2012Article
- Conditions of tumor-associated antigens as a proper target for therapeutic antibodies against solid cancers.Journal of stem cells & regenerative medicine · 2011Article
- Intracellular activation of interferon regulatory factor-1 by nanobodies to the multifunctional (Mf1) domain.The Journal of biological chemistry · 2010Article
- Identification of two aberrant transcripts derived from a hybridoma with amplification of functional immunoglobulin variable genes.Cellular & molecular immunology · 2010Article
- Therapeutic antibodies for the treatment of pancreatic cancer.TheScientificWorldJournal · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 3 institutions in 2 countries.
Funding
Abstract
Pancreatic ductal adenocarcinoma (PDA) is a lethal disease, with surgery being the only curative modality for localized disease, and gemcitabine with or without erlotinib remains the standard of therapy for unresectable or metastatic disease. CEACAM6 is overexpressed in human PDA independent of stage or grade and causes anoikis resistance when dysregulated. Because murine monoclonal antibody 13-1 possesses target-specific cytotoxicity in human PDA cell lines, we designed a humanized anti-CEACAM6 single-chain variable fragment (scFv) based on monoclonal antibody 13-1. PEGylation of the glycine-serine linker was used to enhance plasma half-life. These scFvs bound CEACAM6 with high affinity, exhibited cytotoxic activity, and induced dose-dependent poly(ADP-ribose) polymerase cleavage. Murine PDA xenograft models treated with humanized scFv alone elicited tumor growth inhibition, which was enhanced in combination with gemcitabine. Immunohistochemistry showed significant apoptosis, with inhibition of angiogenesis and proliferation, and preservation of the target. Collectively, our results have important implications for the development of novel antibody-based therapies against CEACAM6 in PDA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.